Fierce Pharma
MARCH 6, 2024
AstraZeneca CEO Pascal Soriot, who has been critical of the U.K.’s business environment for the life sciences industry, is directing a big chunk of money into the Big Pharma’s home country. | AstraZeneca CEO Pascal Soriot, who has been critical of the U.K.’s business environment for the life sciences industry, is directing £650 million into the Big Pharma’s home country.
MedCity News
MARCH 6, 2024
Immersive scenarios in VR allow nursing education programs to enhance and scale the hands-on experiences they provide learners for developing and practicing critical skills.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
MARCH 6, 2024
Two biosimilars to Amgen’s lucrative bone drugs Prolia and Xgeva have clinched approvals at the FDA, though ongoing patent litigation makes launch timing uncertain. | Sandoz has clinched FDA approvals for biosimilars to Amgen’s denosumab. Sandoz’s drugs mark the first approved denosumab biosimilars and treat all indications of the reference products.
MedCity News
MARCH 6, 2024
This case, about the claim that Merck failed to warn patients about the risk of typical femoral fracture, reaches past this suit to potentially change pharmaceutical companies’ relationship with the FDA.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
MARCH 6, 2024
GSK's antiretroviral HIV medicine Tivicay (dolutegravir) has been recommended by the World Health Organization since 2018 as a preferred treatment for the virus. | The World Health Organization (WHO)'s latest HIV Drug Resistance report showed that some patients are developing resistance to Tivicay, which has been recommended as a preferred treatment since 2018.
pharmaphorum
MARCH 6, 2024
A £650 million investment package by AstraZeneca in the UK has been held up by Chancellor Jeremy Hunt as a “vote of confidence” in the country’s life sciences sector. AZ is preparing to invest £450 million at its manufacturing site in Speke, Liverpool, to boost research, development and manufacturing of vaccines, including the construction of a new plant that will be powered by renewable energy, according to a government statement.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Commerce
MARCH 6, 2024
In this Pharmaceutical Commerce video interview, Emma Banks, CEO of ramarketing, discusses how the balance between onshoring and outsourcing will evolve, how long will the current slowdown in biotech investment likely last, and what factors might influence its duration.
MedCity News
MARCH 6, 2024
At ViVE, investors and health system executives shared their biggest pet peeves when it comes to pitches from digital health startups.
Pharmaceutical Technology
MARCH 6, 2024
Demand for medicinal cannabis is increasing globally to treat a range of illnesses and conditions.
European Pharmaceutical Review
MARCH 6, 2024
The US Food and Drug Administration (FDA) has approved the first and only FDA-approved denosumab biosimilars, to treat all indications of the reference medicines. This means that Sandoz ’s Wyost ® (denosumab-bbdz) and Jubbonti ® (denosumab-bbdz) are interchangeable for all indications of reference medicines Xgeva ® (denosumab) and Prolia ® (denosumab).
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
MARCH 6, 2024
NICE has turned down Sanofi’s Xenpozyme as a treatment for the rare disease acid sphingomyelinase deficiency (ASMD), creating a situation where access to the drug in the UK will depend on a patient’s address.
MedCity News
MARCH 6, 2024
A panel discussion of hospital executives at the ViVE event last month offered insight into the challenges of implementing innovation and what they have learned from their experiences.
pharmaphorum
MARCH 6, 2024
Sandoz has claimed the first FDA approvals for biosimilars of Amgen’s blockbuster bone disease therapy denosumab, but has not said when it plans to launch them onto the US market.
MedCity News
MARCH 6, 2024
Women’s health advocates overwhelmingly came out in support of the White House’s $100 million investment into women’s health research. However, some noted shortcomings in where the funding is going.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
PharmaVoice
MARCH 6, 2024
Innovation in schizophrenia has been slow, and patients are often left with few options — but pharmas contribute to a robust lineup of candidates that could improve care.
MedCity News
MARCH 6, 2024
Will 2024 bring any change, or will we witness yet another record- and heart-breaking year of preventable deaths?
pharmaphorum
MARCH 6, 2024
Bayer CEO says company is “badly broken” by patent losses, litigation, debt levels, and bureaucracy, limiting its options for a break-up of the group.
MedCity News
MARCH 6, 2024
Gilead Sciences’ partnership with Merus could yield novel antibody drugs capable of binding to three targets simultaneously. The alliance follows a collaboration that Gilead started last year with Tentarix Biotherapeutics, a startup also developing antibodies that bind to multiple targets.
Pharmaceutical Technology
MARCH 6, 2024
J&J submitted a new application to the EMA for the approval of its Darzalex combination therapy for multiple myeloma.
Healthcare Success
MARCH 6, 2024
Whether you run a multilocation healthcare organization, hospital, or health system, understanding the distinction between search engine optimization (SEO) vs. search engine marketing (SEM)—and how each distinctly helps your business—is important for several reasons. This knowledge helps you: Allocate resources more efficiently. Tailor marketing initiatives to align with specific goals.
PharmaTimes
MARCH 6, 2024
The project will train a newly developed AI system on data collected from participating men and women
Pharmaceutical Technology
MARCH 6, 2024
Experience rapid pain relief with Sorrento Therapeutics' stable oral liquid pharmaceutical composition of celecoxib. Patent filed for effective pain management within 2 hours.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
PharmaTimes
MARCH 6, 2024
CDH affects one in 5,000 babies born in the UK, impacting the foetus’ development of vital organs
Pharmaceutical Technology
MARCH 6, 2024
Discover Avacta Group's groundbreaking patent for therapeutic conjugates with extended half-life, targeting improved efficacy in treating diseases like cancer. Learn more about this innovative approach now!
Pharmaceutical Commerce
MARCH 6, 2024
Navigating the complex landscape of healthcare coverage can be an intimidating task, especially for patients with rare diseases for which treatments often come with a high price tag.
PharmExec
MARCH 6, 2024
In this Pharmaceutical Executive interview, Daniel Ayala, Chief Security and Trust Officer, Dotmatics, dives into the greatest threats to the integrity of data in R&D and threats presented by hackers.
MedCity News
MARCH 6, 2024
At the ViVE event in Los Angeles last month, health tech executives shared how their companies are putting innovative ideas into action to address the most pressing needs in healthcare, as part of the Vibe at ViVE by MedCity News.
Clarivate
MARCH 6, 2024
For 13 years, Clarivate has identified the organizations leading the world in technology research and innovation. As the pace of innovation continues to accelerate and competition intensifies, we introduce the Top 100 Global Innovators 2024. This year, ranked. 2024 report key findings Samsung Electronics ranks first in the Top 100 Global Innovators 2024.
PharmaVoice
MARCH 6, 2024
An all-out blitz across U.S. courts is bolstering pharma’s goal to overturn Medicare drug price negotiations.
Zymewire
MARCH 6, 2024
Best practices for crafting effective cold outreach messages to biotech and pharma companies as we go up against AI (ChatGPT) in a could outreach face off
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
344 
Let's personalize your content